Jingming Wang

Jingming Wang is a molecular and cellular biologist at VantAI. Jingming is responsible for experimental design, data analysis, and machine learning drug design for VantAI's machine learning platform.

Wang received their PhD in pharmacology from Stony Brook University in 2018. Jingming's research focused on the correlation of the PIN1 and FAAP20 protein levels in acute myeloid leukemia. Jingming also completed a clinical immersion program at Stony Brook Medicine in 2014.

Prior to joining VantAI, Wang was a visiting investigator at Memorial Sloan Kettering Cancer Center from 2019 to 2021. Jingming was also a trainee of the Scholars in Biomedical Sciences program at Stony Brook Medicine from 2016 to 2017.

Jingming Wang has a Doctor of Philosophy (Ph.D.) in Molecular & Cell Pharmacology from Stony Brook University. Jingming also has a Bachelor’s Degree in Biology&Chemistry from Central China Normal University. Jingming is certified from Stony Brook Medicine in Scholars in Biomedical Sciences.

Some of their coworkers include Si-Han Chen - Head of Computational Chemistry, Cristina Di Genua - E3 Systems Biologist, and Allison Cohen - Accounting Manager. Jingming Wang reports to Zachary Carpenter, CEO.